Figure 1 | Scientific Reports

Figure 1

From: Plasma proteome profiling reveals the therapeutic effects of the PPAR pan-agonist chiglitazar on insulin sensitivity, lipid metabolism, and inflammation in type 2 diabetes

Figure 1

Overview of the study design and the multivariate Cox regression analysis of different parameters on blood glucose-lowering effects. (A) Patients who met the filter criteria took chiglitazar (N = 103), sitagliptin (N = 31), or placebo (N = 23) for 24 weeks, and plasma samples and clinical variables were collected and measured at 3 time points, including before the first time taking the drug (baseline) and every 12 weeks after daily medication intake. (B) Forest plot showing multivariate Cox regression analysis of the effect of treatment, age, sex, body mass index (BMI), and baseline level of blood glucose parameters on blood glucose-lowering effects (N = 157). PBG, postprandial blood glucose; FPG, fasting plasma glucose; FINS, fasting insulin.

Back to article page